Publications by authors named "M M Loriaux"
Article Synopsis
- Acute myeloid leukemia (AML) is a challenging cancer with few treatment options, and the study combines ex vivo drug sensitivity with genomic data from 805 patients to better understand treatment responses.
- This research identifies key features influencing drug sensitivity, particularly focusing on the differentiation state of AML cells, which has implications for how they respond to therapy.
- Notably, the gene PEAR1 emerges as a strong predictor of survival in young AML patients, highlighting its potential role in guiding treatment decisions and future drug development.
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with approximately four new cases per 100,000 persons per year. Standard treatment for AML consists of induction chemotherapy with remission achieved in 50 to 75% of cases. Unfortunately, most patients will relapse and die from their disease, as 5-y survival is roughly 29%.
View Article and Find Full Text PDFTo identify new therapeutic targets in acute myeloid leukemia (AML), we performed small-molecule and small-interfering RNA (siRNA) screens of primary AML patient samples. In 23% of samples, we found sensitivity to inhibition of colony-stimulating factor 1 (CSF1) receptor (CSF1R), a receptor tyrosine kinase responsible for survival, proliferation, and differentiation of myeloid-lineage cells. Sensitivity to CSF1R inhibitor GW-2580 was found preferentially in de novo and favorable-risk patients, and resistance to GW-2580 was associated with reduced overall survival.
View Article and Find Full Text PDF